SCHEMBL4867531

SCHEMBL4867531

Fc1cccc(CNc2nc(-c3ccccc3)nc3ccccc23)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.76
KMT2A Q03164 6/20 0.76
LMNA P02545 5/20 0.76
MAPT P10636 2/20 0.76
PDE5A O76074 10/20 0.75
GBA1 P04062 3/20 0.75
ATM Q13315 1/20 0.75
APP P05067 1/20 0.71
CCNE2 O96020 1/20 0.68
CCNE1 P24864 1/20 0.68
CDK2 P24941 1/20 0.68
PTGS1 P23219 2/20 0.64
TBXAS1 P24557 2/20 0.64
PTGS2 P35354 2/20 0.64
ABCG2 Q9UNQ0 1/20 0.64
ALDH1A1 P00352 5/20 0.64
CYP1A2 P05177 5/20 0.64
CYP3A4 P08684 5/20 0.64
CYP2D6 P10635 5/20 0.64
CYP2C19 P33261 5/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22201360 0.93 PDE5A (0.77) MEN1KMT2ALMNAMAPTPDE5A
SCHEMBL4867611 0.92 PDE5A (0.73) MEN1KMT2ALMNAMAPTPDE5A
SCHEMBL4856772 0.88 GBA1 (0.82) MEN1KMT2ALMNAMAPTPDE5A
SCHEMBL1084183 0.87 MEN1 (0.89) MEN1KMT2ALMNAMAPTPDE5A
SCHEMBL2583554 0.87 MEN1 (1.00) MEN1KMT2ALMNAMAPTPDE5A
SCHEMBL1083763 0.86 PDE5A (1.00) MEN1KMT2ALMNAMAPTPDE5A
SCHEMBL4863906 0.85 PDE5A (0.75) MEN1KMT2ALMNAMAPTPDE5A
SCHEMBL2590473 0.85 PDE5A (1.00) MEN1KMT2ALMNAMAPTPDE5A
SCHEMBL2580376 0.84 RAD52 (0.76) MEN1KMT2ALMNAMAPTAPP
SCHEMBL4864021 0.84 APP (0.73) MEN1KMT2ALMNAMAPTPDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R MEN1 3837/4885KMT2A 1662/4885LMNA 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.